Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study-Reference-Cited by-同舟云学术

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

Published:2013-12-24 Issue:4 Volume:74 Page:694-702
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

McInnes Iain B,Thompson Liz,Giles Jon T,Bathon Joan M,Salmon Jane E,Beaulieu Andre D,Codding Christine E,Carlson Timothy H,Delles Christian,Lee Janet S,Sattar Naveed

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference31 articles.

1. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis;Peters;Ann Rheum Dis,2010

2. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis;Gonzalez-Gay;Arthritis Rheum,2007

3. Role for TNF in atherosclerosis? Lessons from autoimmune disease;McKellar;Nat Rev Cardiol,2009

4. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis;Sattar;Circulation,2003

5. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile;Hurt-Camejo;Arthritis Rheum,2001

Cited by 243 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients;Seminars in Arthritis and Rheumatism;2024-10

2. Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases;Nature Reviews Rheumatology;2024-09-02

3. The impact of biologic agents on cardiovascular risk factors in patients with rheumatoid arthritis: A meta analysis;PLOS ONE;2024-08-29

4. Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs;Drugs;2024-07-01

5. Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis;European Journal of Internal Medicine;2024-07